Sign in or create an account to add this stock to your watchlist.
About AzurRx BioPharma (NASDAQ:AZRX)
AzurRx BioPharma, Inc. researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea. The company was incorporated in 2014 and is headquartered in Brooklyn, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AZRX
CUSIPN/A
Phone646-699-7855
Debt
Debt-to-Equity RatioN/A
Current Ratio0.64
Quick Ratio0.64
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.07 per share
Price / Book34.43
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-11,090,000.00
Net MarginsN/A
Return on Equity-468.72%
Return on Assets-181.43%
Miscellaneous
Employees13
Outstanding Shares16,760,000
AzurRx BioPharma (NASDAQ:AZRX) Frequently Asked Questions
What is AzurRx BioPharma's stock symbol?
AzurRx BioPharma trades on the NASDAQ under the ticker symbol "AZRX."
How were AzurRx BioPharma's earnings last quarter?
AzurRx BioPharma (NASDAQ:AZRX) posted its quarterly earnings results on Monday, May, 14th. The company reported ($0.29) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.18) by $0.11. View AzurRx BioPharma's Earnings History.
When is AzurRx BioPharma's next earnings date?
What price target have analysts set for AZRX?
1 brokerages have issued 12 month price targets for AzurRx BioPharma's stock. Their predictions range from $6.00 to $6.00. On average, they anticipate AzurRx BioPharma's stock price to reach $6.00 in the next twelve months. View Analyst Ratings for AzurRx BioPharma.
Who are some of AzurRx BioPharma's key competitors?
Some companies that are related to AzurRx BioPharma include BioXcel Therapeutics (BTAI), Newron Pharmaceuticals (NWPHF), AcelRx Pharmaceuticals (ACRX), Spero Therapeutics (SPRO), Eleven Biotherapeutics (EBIO), Affimed (AFMD), Intec Pharma (NTEC), Galectin Therapeutics Inc. Common Stock (GALT), XBiotech (XBIT), Adamis Pharmaceuticals (ADMP), Teligent (TLGT), RedHill Biopharma (RDHL), Zynerba Pharmaceuticals (ZYNE), Acer Therapeutics (ACER) and Forward Pharma (FWP).
Who are AzurRx BioPharma's key executives?
AzurRx BioPharma's management team includes the folowing people:
- Mr. Johan M. Spoor, Pres, CEO & Director (Age 46)
- Mr. Maged S. Shenouda, CFO, Exec. VP & Director (Age 54)
- Mr. Daniel Dupret, Chief Scientific Officer (Age 62)
- Dr. Mathieu Schué Ph.D., Head of Laboratory
- Mr. Martin Krusin, VP of Fin. & Bus. Devel.
When did AzurRx BioPharma IPO?
(AZRX) raised $15 million in an initial public offering (IPO) on Friday, September 9th 2016. The company issued 2,100,000 shares at a price of $6.00-$8.00 per share. WallachBeth Capital and Network 1 Financial Securities served as the underwriters for the IPO.
Has AzurRx BioPharma been receiving favorable news coverage?
Media stories about AZRX stock have been trending very positive recently, Accern Sentiment Analysis reports. Accern rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AzurRx BioPharma earned a media sentiment score of 0.52 on Accern's scale. They also assigned news headlines about the company an impact score of 47.94 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are AzurRx BioPharma's major shareholders?
Which institutional investors are buying AzurRx BioPharma stock?
How do I buy shares of AzurRx BioPharma?
Shares of AZRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AzurRx BioPharma's stock price today?
One share of AZRX stock can currently be purchased for approximately $2.41.
How big of a company is AzurRx BioPharma?
AzurRx BioPharma has a market capitalization of $41.74 million. AzurRx BioPharma employs 13 workers across the globe.
How can I contact AzurRx BioPharma?
AzurRx BioPharma's mailing address is 760 PARKSIDE AVENUE SUITE 304, BROOKLYN NY, 11226. The company can be reached via phone at 646-699-7855 or via email at [email protected]
MarketBeat Community Rating for AzurRx BioPharma (AZRX)
MarketBeat's community ratings are surveys of what our community members think about AzurRx BioPharma and other stocks. Vote "Outperform" if you believe AZRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AZRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
AzurRx BioPharma (NASDAQ:AZRX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for AzurRx BioPharma in the last 12 months. Their average twelve-month price target is $6.00, suggesting that the stock has a possible upside of 148.96%. The high price target for AZRX is $6.00 and the low price target for AZRX is $6.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $6.00 | $8.00 | $8.00 | $7.50 |
| Price Target Upside: | 148.96% upside | 164.03% upside | 134.60% upside | 158.62% upside |
AzurRx BioPharma (NASDAQ:AZRX) Consensus Price Target History
AzurRx BioPharma (NASDAQ:AZRX) Analyst Ratings History
Show:
(Data available from 5/25/2016 forward)
AzurRx BioPharma (NASDAQ:AZRX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
AzurRx BioPharma (NASDAQ AZRX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.10%
Institutional Ownership Percentage: 4.47%
AzurRx BioPharma (NASDAQ AZRX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 6/30/2017 | Pelican Partners Llc | Major Shareholder | Sell | 160,000 | $3.19 | $510,400.00 | 1,787,796 |  |
(Data available from 1/1/2013 forward)
AzurRx BioPharma (NASDAQ AZRX) News Headlines
| Source: |
|
AzurRx BioPharma (NASDAQ:AZRX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
AzurRx BioPharma (NASDAQ:AZRX) Income Statement, Balance Sheet and Cash Flow Statement
AzurRx BioPharma (NASDAQ AZRX) Stock Chart for Friday, May, 25, 2018
Loading chart…
